Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative

BackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the L...

Full description

Bibliographic Details
Main Authors: Muh. Akbar Bahar, Jens H. J. Bos, Sander D. Borgsteede, Aafje Dotinga, Rolinde A. Alingh, Bob Wilffert, Eelko Hak
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00624/full
id doaj-0fe60b47876e442bbf49c0c4a06d41cf
record_format Article
spelling doaj-0fe60b47876e442bbf49c0c4a06d41cf2020-11-25T03:32:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-05-011110.3389/fphar.2020.00624512495Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines InitiativeMuh. Akbar Bahar0Muh. Akbar Bahar1Jens H. J. Bos2Sander D. Borgsteede3Aafje Dotinga4Rolinde A. Alingh5Bob Wilffert6Bob Wilffert7Eelko Hak8Unit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsFaculty of Pharmacy, Hasanuddin University, Makassar, IndonesiaUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsDepartment of Clinical Decision Support, Health Base Foundation, Utrecht, NetherlandsLifelines Cohort Study, Lifelines Databeheer B.V., Roden, NetherlandsLifelines Cohort Study, Lifelines Databeheer B.V., Roden, NetherlandsUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, NetherlandsUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsBackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.MethodsAs part of the University of Groningen PharmLines Initiative, data were collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires of Lifelines participants and linked information from the pharmacy database IADB.nl. CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e. chronically used medication (CM) or occasionally used medication (OM). This resulted in the combination of two chronically used drugs (CM-CM), chronically and occasionally used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the agreement level, cohen’s kappa statistics and test characteristics were used. Results were stratified by time window, gender, and age.ResultsAmong 80,837 medicine users in the Lifelines, about 1–2 per hundred participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall, the overlapping time window of three months produced the highest mean kappa values between the databases i.e. 0.545 (95% CI:0.544–0.545), 0.512 (95% CI:0.511–0.512), and 0.374 (95% CI:0.373–0.375), respectively. CM-CM had a better level of agreement (good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The influence of gender on concordance values was different for different CYPs. Among older persons, agreement levels were higher than for the younger population.ConclusionsCYP2D6/2C19/2C9-mediated potential DDIs were frequent and concordance of data varied by time window, type of combination, sex and age. Subsequent studies should rather use a combination of self-reported and pharmacy database information.https://www.frontiersin.org/article/10.3389/fphar.2020.00624/fullCYP2D6CYP2C19CYP2C9drug-drug-interactionLifelinesIADB.nl
collection DOAJ
language English
format Article
sources DOAJ
author Muh. Akbar Bahar
Muh. Akbar Bahar
Jens H. J. Bos
Sander D. Borgsteede
Aafje Dotinga
Rolinde A. Alingh
Bob Wilffert
Bob Wilffert
Eelko Hak
spellingShingle Muh. Akbar Bahar
Muh. Akbar Bahar
Jens H. J. Bos
Sander D. Borgsteede
Aafje Dotinga
Rolinde A. Alingh
Bob Wilffert
Bob Wilffert
Eelko Hak
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
Frontiers in Pharmacology
CYP2D6
CYP2C19
CYP2C9
drug-drug-interaction
Lifelines
IADB.nl
author_facet Muh. Akbar Bahar
Muh. Akbar Bahar
Jens H. J. Bos
Sander D. Borgsteede
Aafje Dotinga
Rolinde A. Alingh
Bob Wilffert
Bob Wilffert
Eelko Hak
author_sort Muh. Akbar Bahar
title Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
title_short Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
title_full Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
title_fullStr Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
title_full_unstemmed Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
title_sort prevalence and accuracy of information on cyp2d6, cyp2c19, and cyp2c9 related substrate and inhibitor co-prescriptions in the general population: a cross‐sectional descriptive study as part of the pharmlines initiative
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-05-01
description BackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.MethodsAs part of the University of Groningen PharmLines Initiative, data were collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires of Lifelines participants and linked information from the pharmacy database IADB.nl. CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e. chronically used medication (CM) or occasionally used medication (OM). This resulted in the combination of two chronically used drugs (CM-CM), chronically and occasionally used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the agreement level, cohen’s kappa statistics and test characteristics were used. Results were stratified by time window, gender, and age.ResultsAmong 80,837 medicine users in the Lifelines, about 1–2 per hundred participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall, the overlapping time window of three months produced the highest mean kappa values between the databases i.e. 0.545 (95% CI:0.544–0.545), 0.512 (95% CI:0.511–0.512), and 0.374 (95% CI:0.373–0.375), respectively. CM-CM had a better level of agreement (good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The influence of gender on concordance values was different for different CYPs. Among older persons, agreement levels were higher than for the younger population.ConclusionsCYP2D6/2C19/2C9-mediated potential DDIs were frequent and concordance of data varied by time window, type of combination, sex and age. Subsequent studies should rather use a combination of self-reported and pharmacy database information.
topic CYP2D6
CYP2C19
CYP2C9
drug-drug-interaction
Lifelines
IADB.nl
url https://www.frontiersin.org/article/10.3389/fphar.2020.00624/full
work_keys_str_mv AT muhakbarbahar prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT muhakbarbahar prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT jenshjbos prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT sanderdborgsteede prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT aafjedotinga prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT rolindeaalingh prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT bobwilffert prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT bobwilffert prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
AT eelkohak prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative
_version_ 1724569689125814272